Novel pathways regulating glucose and lipid metabolism in human skeletal muscle
Author: Austin, Reginald L
Date: 2009-04-27
Location: Farmakologens föreläsningssal, Karolinska Institutet, Solna
Time: 13.00
Department: Institutionen för molekylär medicin och kirurgi / Department of Molecular Medicine and Surgery
View/ Open:
Thesis (1.149Mb)
Abstract
The utilization of glucose and lipids as energy substrates in skeletal
muscle is strictly regulated. As skeletal muscle is the body s chief
consumer of glucose and lipids, it plays a critical role in the
maintenance of whole-body homeostasis. Under normal physiological
conditions, skeletal muscle displays a certain metabolic flexibility,
allowing the tissue to switch between the utilization of glucose and
lipids. Generally, skeletal muscle manifests a preference for lipids as
the primary energy substrate, in the fasting state, or during such
metabolic challenges as starvation or exercise. In these situations,
glucose availability is low. However, in the post-prandial state, glucose
availability is high and energy substrate utilization is shifted toward
glucose. A compromised or reduced plasticity in this ability to shift
substrate utilization results in metabolic inflexibility. Conditions
associated with metabolic inflexibility include the metabolic syndrome,
insulin resistance and type 2 diabetes mellitus. To address the etiology
and pathogenesis of these disorders, investigation of the molecular
events governing these processes is warranted. In this thesis, novel
pathways regulating glucose and lipid metabolism in human skeletal muscle
were investigated with the specific aim of discovering and validating new
potential therapeutic targets to treat type 2 diabetes.
Cultured primary human skeletal muscle cells were used to determine the consequence of targeted malonyl CoA decarboxylase (MCD) (Study I), and inhibitor of nuclear factor kappaB kinase (IKKbeta) (Study II), reduction on metabolic and signaling parameters. The effect of exogenous fibroblast growth factor 21 (FGF-21) (Study III) and clenbuterol treatment (Study IV) on metabolic and signaling parameters were also determined. Targeted genetic reduction of either MCD or IKKbeta increased glucose uptake and improved insulin signaling in cultured muscle cells. MCD reduction was sufficient to shift substrate utilization from lipid to glucose oxidation. IKKbeta gene silencing prevented TNF-alpha-mediated insulin resistance in cultured human skeletal muscle. FGF-21 is a novel member of the fibroblast growth factor family of proteins, distinguished by its hormone-like action on metabolism. FGF-21 treatment positively impacted glucose metabolism in human skeletal muscle cells and in incubated intact mouse skeletal muscle. Finally, chronic clenbuterol exposure was sufficient to increase glycogen synthesis, and reduce lipid oxidation in human skeletal muscle myotubes and in cultured rat L6 muscle cells.
In conclusion, the studies presented in this thesis provide insight into molecular pathways governing glucose and lipid metabolism in skeletal muscle. Several new targets have been identified and validated for potential therapeutic intervention to treat insulin resistance. Moreover, these investigations provide insight not only into the signaling paradigm of a particular pathway but rather into the interconnectivity of complex metabolic regulation.
Cultured primary human skeletal muscle cells were used to determine the consequence of targeted malonyl CoA decarboxylase (MCD) (Study I), and inhibitor of nuclear factor kappaB kinase (IKKbeta) (Study II), reduction on metabolic and signaling parameters. The effect of exogenous fibroblast growth factor 21 (FGF-21) (Study III) and clenbuterol treatment (Study IV) on metabolic and signaling parameters were also determined. Targeted genetic reduction of either MCD or IKKbeta increased glucose uptake and improved insulin signaling in cultured muscle cells. MCD reduction was sufficient to shift substrate utilization from lipid to glucose oxidation. IKKbeta gene silencing prevented TNF-alpha-mediated insulin resistance in cultured human skeletal muscle. FGF-21 is a novel member of the fibroblast growth factor family of proteins, distinguished by its hormone-like action on metabolism. FGF-21 treatment positively impacted glucose metabolism in human skeletal muscle cells and in incubated intact mouse skeletal muscle. Finally, chronic clenbuterol exposure was sufficient to increase glycogen synthesis, and reduce lipid oxidation in human skeletal muscle myotubes and in cultured rat L6 muscle cells.
In conclusion, the studies presented in this thesis provide insight into molecular pathways governing glucose and lipid metabolism in skeletal muscle. Several new targets have been identified and validated for potential therapeutic intervention to treat insulin resistance. Moreover, these investigations provide insight not only into the signaling paradigm of a particular pathway but rather into the interconnectivity of complex metabolic regulation.
List of papers:
I. Bouzakri K, Austin R, Rune A, Lassman ME, Garcia-Roves PM, Berger JP, Krook A, Chibalin AV, Zhang BB, Zierath JR (2008). "Malonyl CoenzymeA decarboxylase regulates lipid and glucose metabolism in human skeletal muscle." Diabetes 57(6): 1508-16. Epub 2008 Feb 26
Pubmed
II. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A (2008). "siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle." Diabetes 57(8): 2066-73. Epub 2008 Apr 28
Pubmed
III. Austin RL, Deshmuk AS, Zierath JR, Krook A (2009). "Direct effect of FGF-21 on skeletal muscle glucose uptake." (Manuscript)
IV. Austin RL, Fahlman, R, Long YC, Krook A, Al-Khalili L (2009). "Effects of clenbuterol on glucose and lipid metabolism in skeletal muscle." (Manuscript)
I. Bouzakri K, Austin R, Rune A, Lassman ME, Garcia-Roves PM, Berger JP, Krook A, Chibalin AV, Zhang BB, Zierath JR (2008). "Malonyl CoenzymeA decarboxylase regulates lipid and glucose metabolism in human skeletal muscle." Diabetes 57(6): 1508-16. Epub 2008 Feb 26
Pubmed
II. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A (2008). "siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle." Diabetes 57(8): 2066-73. Epub 2008 Apr 28
Pubmed
III. Austin RL, Deshmuk AS, Zierath JR, Krook A (2009). "Direct effect of FGF-21 on skeletal muscle glucose uptake." (Manuscript)
IV. Austin RL, Fahlman, R, Long YC, Krook A, Al-Khalili L (2009). "Effects of clenbuterol on glucose and lipid metabolism in skeletal muscle." (Manuscript)
Issue date: 2009-04-06
Rights:
Publication year: 2009
ISBN: 978-91-7409-448-0
Statistics
Total Visits
Views | |
---|---|
Novel ...(legacy) | 759 |
Novel ... | 144 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Novel ... | 1 | 0 | 2 | 1 | 0 | 0 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 401 |
thesis.pdf | 100 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 420 |
Sweden | 78 |
China | 72 |
Germany | 55 |
Finland | 15 |
South Korea | 15 |
United Kingdom | 11 |
Russia | 11 |
Denmark | 7 |
Ireland | 7 |
Top cities views
Views | |
---|---|
Beijing | 32 |
Romeo | 28 |
Sunnyvale | 27 |
Uppsala | 21 |
Kiez | 18 |
Seoul | 15 |
Lansing | 12 |
Ashburn | 7 |
Dublin | 7 |
Stockholm | 7 |